Compare PROF & RLMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PROF | RLMD |
|---|---|---|
| Founded | N/A | 2004 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 270.7M | 319.7M |
| IPO Year | 2017 | 2012 |
| Metric | PROF | RLMD |
|---|---|---|
| Price | $7.48 | $4.80 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 4 |
| Target Price | ★ $12.00 | $10.25 |
| AVG Volume (30 Days) | 145.3K | ★ 587.6K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 19.21 |
| EPS | ★ 1.14 | N/A |
| Revenue | ★ $10,680,000.00 | $13,070.00 |
| Revenue This Year | $61.09 | N/A |
| Revenue Next Year | $120.94 | N/A |
| P/E Ratio | $6.41 | ★ N/A |
| Revenue Growth | 48.35 | ★ 154.83 |
| 52 Week Low | $3.90 | $0.24 |
| 52 Week High | $8.95 | $5.12 |
| Indicator | PROF | RLMD |
|---|---|---|
| Relative Strength Index (RSI) | 55.25 | 61.68 |
| Support Level | $5.31 | $3.49 |
| Resistance Level | $7.95 | $5.05 |
| Average True Range (ATR) | 0.42 | 0.35 |
| MACD | 0.10 | 0.08 |
| Stochastic Oscillator | 75.38 | 89.73 |
Profound Medical Corp is a commercial-stage medical device company focused on the development and marketing of customizable, incision-free therapeutic systems for the image-guided ablation of diseased tissue utilizing its platform technologies and leveraging the healthcare system's existing imaging infrastructure. The company's product TULSA-PRO system combines real-time MRI, robotically driven transurethral sweeping-action thermal ultrasound with closed-loop temperature feedback control for the ablation of prostate tissue. The product is comprised of one-time-use devices and durable equipment that are used in conjunction with a customer's existing MRI scanner.
Relmada Therapeutics Inc is a clinical-stage biotechnology company. It is engaged in developing chemical entities with novel versions of drug products that address areas of high unmet medical need in the treatment of central nervous system diseases. The company is focused on the development of esmethadone (d-methadone, dextromethadone, REL-1017), an N-methyl-D-aspartate (NMDA) receptor antagonist. Its key product candidate, esmethadone, is an oral agent for the treatment of depression and other potential indications.